91105-97-4

Usage

Uses

Used in Organic Synthesis:
3-Methoxy-N-methylisatoic anhydride is used as a reagent in organic synthesis for the preparation of various chemical compounds. Its unique structure allows for the creation of a wide range of products, making it a valuable asset in the field of chemistry.
Used in Pharmaceutical Preparation:
As an intermediate in the preparation of pharmaceuticals, 3-Methoxy-N-methylisatoic anhydride plays a crucial role in the development of new drugs. Its ability to be incorporated into the molecular structures of potential medications contributes to the advancement of pharmaceutical research and development.
Used in the Synthesis of Heterocyclic Compounds:
3-Methoxy-N-methylisatoic anhydride is utilized in the synthesis of heterocyclic compounds, which are an important class of organic compounds with applications in various fields, including pharmaceuticals, agrochemicals, and materials science.
Used in Protein and Peptide Modification:
In the field of biochemistry, 3-Methoxy-N-methylisatoic anhydride is used for the modification of proteins and peptides. Its ability to form novel conjugates or bioconjugates has significant implications for the development of new bioactive molecules and therapeutic agents.
Used in Biological Activity and Pharmacological Research:
3-Methoxy-N-methylisatoic anhydride is being studied for its potential biological activities and pharmacological properties. Its exploration in these areas could lead to the discovery of new applications in medicine and other related fields.

Upstream product

• 67765-42-8 5-methoxy-2,4-dihydro-1H-3,1-benzoxazine-2,4-dione 
• 74-88-4 methyl iodide 
• 53600-33-2 6-methoxyanthranilic acid 
• 75-44-5 phosgene 
• 254964-68-6 6-methoxy-N-methyl-anthranilic acid 
• 1332581-19-7 2-methoxy-6-(methylamino)benzonitrile 
• 1897-52-5 2,6 difluorobenzonitrile 

Downstream Products

• 248282-13-5 1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxylic acid ethyl ester 
• 254964-60-8 1,2-dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide 
• 248282-18-0 1,2-Dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket

Clinical use of phosphodiesterase-5 (PDE5) inhibitors is limited by several side effects due to weak isoform selectivity. Herein, a unique allosteric pocket of PDE5 is identified by molecular modeling and structural biology, which enables the discovery of highly selective PDE5 inhibitors from natural product evodiamine (EVO). The crystal structure of PDE5 with bound EVO derivative (S)-7e revealed that binding of (S)-7e to the novel allosteric pocket induced dramatic conformation changes in the H-loop with a maximum 24 ? movement of their Cα atoms. This movement directly blocks the binding of substrate/inhibitors to the PDE5 active site, which is different from all traditional PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil. These derivatives showed >570-fold selectivity over PDE6C and PDE11A and achieved potent efficacy for the effective treatment of pulmonary hypertension in vivo.

Evodiamine compounds and preparation method and application thereof

The invention discloses evodiamine compounds and a preparation method and application thereof. The evodiamine compounds adopt structures shown as a general formula (I), and comprise racemates, d-type or l-type isomers and pharmaceutically acceptable salts thereof. Pharmacological tests prove that the evodiamine compounds have obvious phosphodiesterase PDE5 inhibiting activity, some of the evodiamine compounds have equivalent PDE5 inhibiting activity to sildenafil, and the evodiamine compounds have stronger phosphodiesterase PDE6 selectivity. The evodiamine compounds can be clinically used for improving or treating symptoms or diseases in a cardiovascular system, a cerebrovascular system and a urinary system, especially improving or treating symptoms or diseases including erectile dysfunction and pulmonary hypertension.

Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure-Activity Relationship

Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).

QUINOLINE DERIVATIVES

The invention is related to compounds of general formula (I), wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R' is methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, or OCHxFy, wherein x = O - 2, y = 1 - 3 with the proviso that x + y = 3; R'' is hydrogen, fluoro or chloro; with the proviso that R'' is fluoro or chloro only when R' is fluoro; R4 is hydrogen or pharmaceutically acceptable inorganic or organic cations; R5 is ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, trifluoromethyl, OCHxFy, or OCH2CHxFy wherein x = 0 - 2, y = 1 - 3 with the proviso that x + y = 3; R6 is hydrogen; or R5, and R6 taken together are methylenedioxy; and any tautomer thereof. The invention also relates to pharmaceutical compositions containing a compound of general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering of a compound having formula (I) to said mammal.

4-(aroylamino)piperidine-butanimide derivatives

A method of treating warm-blooded animals suffering from diarrhea, which method comprises the administration of particular 4-(aroylamino)piperidinebutanamide derivatives and compositions containing the same. Novel 4-(aroylamino)piperidinebutanamide deriva